Dreaming of entering the global market by developing autism treatment!

19-07-15

Development of iGluR signal transduction target therapy

I will establish myself as a hope for autistic patients

[Medicine News Daily = Reporter Ahn Chi-young] Neuroventi (CEO Shin Chan-young) is an autism treatment development company that opened in 2015. Neuroventi, derived from the company slogan of 'The brain shield for venti-sized brain function', discovers disease-based, big data, and AI-based disease overcoming targets and develops autism spectrum disorder. We are focusing on drug development.

Shin Chan-yeong, CEO of Neuroventy, completed a post-doctoral course at the Department of Molecular, Cellular and Developmental Biology at Yale University in the United States, obtained a teaching position in Korea, and researched a developmental disorder called autism, which was unfamiliar to the word in the process of preparing to return home. Bora came into contact with the voice in her heart. Upon investigation, there were a total of 7 papers published in Korea at the time, and even those papers were all case reports, so CEO Shin considered this field his calling and conducted animal model development, risk factor identification, and pharmacological target identification research. .

One day, while trying to find treatment candidates for autism spectrum disorder for which there is no suitable treatment, we held an autism symposium for scientists, therapists, childcare teachers, and people with ASD disabilities and their caregivers together with clinicians. While watching the symposium, which started early in the morning, and the majority of parents stayed in their seats until the symposium was closed in the evening, CEO Shin realized how desperately necessary it was to develop an appropriate treatment, and utilized the results of basic research in the development of a full-fledged treatment. , I decided to devote myself to advancing the time when treatment for developmental disabilities is possible.

Building on this foundation, Neuroventi's contribution to the field of autism is substantial. According to Neuroventi, research on autism so far is a patient-based clinical study and is not applicable to all patients due to the nature of heterozygous disease, but usually changes in brain size (macrocephaly / microcephaly), increase in the number of neurons, excitability Disruption of the inhibitory neurotransmission balance has been identified as a major phenomenon.

Symptomatic treatment drugs currently being used are confined to reducing symptoms of hyperactivity (Methylphenidate) and reducing aggression (Haloperidol, Risperidone), and do not show an effect on the lack of sociality, which is a major symptom of autism.

Newly proposed autism treatment targets are deeply related to excitatory/inhibitory signal transduction imbalance, and the mGluR system, NMDA receptor antagonists, and GABA receptor agonists have been suggested.

Neuroventi explained that these targets are likely to be effective only in some autistic patients, and therefore, the probability of clinical success is not high due to low efficiency and large side effects. Unlike them, Neuroventi is developing drugs that target the regulation of endogenous iGluR signaling and inhibition of excessive excitatory nerve activity.

CEO Shin Chan-young said, “The presentation of a patient-specific treatment target will be a game changer in this field.” “In addition to FDA-approved drugs (Risperidone, Aripiprazole) as a treatment for hypersensitivity, which is a symptom of autism, several antipsychotic tranquilizer drugs are being used off-label. Under these circumstances, if the development of a treatment succeeds, it can secure its status as a new drug,” he emphasized.

Currently, Neuroventi has entered preclinical trials to develop a treatment for autism spectrum disorder, and has secured a follow-up pipeline. Through strategic alliances with domestic pharmaceutical companies, it plans to increase the efficiency of treatment development and secure sales routes, and is also considering global technology transfer.

In addition to medicines, we provide customized nootropic supplements to provide appropriate nutrients needed for autism patients, improve autism, and provide therapeutic effects. In addition, it provides a development platform for discovery of natural HTS-based health food/health functional food and drug candidates.

Although Neuroventi has been on the path to developing new drugs to some extent, the initial set-up involved considerable effort. CEO Shin said, “There are advantages in that it is a start-up, but it was difficult to secure excellent human resources due to the difference in welfare and salary compared to large companies.” We need an institutional device so that we can succeed through this,” he said.

Shin Chan-young, CEO of Neuroventi, who is growing as a new drug development company after taking the first step of starting a business, advises young people who are looking to start a health care business and jump into it, 'don't be afraid to take on challenges with a sense of purpose'.

CEO Shin said, “A business must eventually create economic profits, but please do not be afraid to do what you set out to do and develop medicines and medical devices that are essential in Korea and around the world.” It is the most important start that can lead to